KR950701685A - 단일클론 항체(monoclonal antibodies) - Google Patents

단일클론 항체(monoclonal antibodies)

Info

Publication number
KR950701685A
KR950701685A KR1019940704163A KR19940704163A KR950701685A KR 950701685 A KR950701685 A KR 950701685A KR 1019940704163 A KR1019940704163 A KR 1019940704163A KR 19940704163 A KR19940704163 A KR 19940704163A KR 950701685 A KR950701685 A KR 950701685A
Authority
KR
South Korea
Prior art keywords
monoclonal antibodies
monoclonal
cancer
antibodies
prophylactic
Prior art date
Application number
KR1019940704163A
Other languages
English (en)
Other versions
KR100279317B1 (ko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929210944A external-priority patent/GB9210944D0/en
Priority claimed from GB929210930A external-priority patent/GB9210930D0/en
Priority claimed from GB929210929A external-priority patent/GB9210929D0/en
Application filed filed Critical
Publication of KR950701685A publication Critical patent/KR950701685A/ko
Application granted granted Critical
Publication of KR100279317B1 publication Critical patent/KR100279317B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Wood Science & Technology (AREA)
KR1019940704163A 1992-05-22 1993-05-14 단일클론항체 KR100279317B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB929210944A GB9210944D0 (en) 1992-05-22 1992-05-22 Monoclonal antibodies and their use
GB9210929.7 1992-05-22
GB929210930A GB9210930D0 (en) 1992-05-22 1992-05-22 Monoclonal antibodies and their use
GB9210944.6 1992-05-22
GB929210929A GB9210929D0 (en) 1992-05-22 1992-05-22 Monoclonal antibodies and their use
GB9210930.5 1992-05-22
PCT/EP1993/001215 WO1993024647A1 (en) 1992-05-22 1993-05-14 Anti-idiotypic monoclonal antibodies against the lewis y-specific monoclonal antibody br55-2 and their uses

Publications (2)

Publication Number Publication Date
KR950701685A true KR950701685A (ko) 1995-04-28
KR100279317B1 KR100279317B1 (ko) 2001-01-15

Family

ID=27266199

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940704163A KR100279317B1 (ko) 1992-05-22 1993-05-14 단일클론항체

Country Status (20)

Country Link
EP (1) EP0644947B1 (ko)
JP (3) JPH07507207A (ko)
KR (1) KR100279317B1 (ko)
AT (1) ATE179214T1 (ko)
AU (1) AU678160B2 (ko)
CA (1) CA2134751C (ko)
CZ (1) CZ286547B6 (ko)
DE (1) DE69324584T2 (ko)
DK (1) DK0644947T3 (ko)
ES (1) ES2133395T3 (ko)
FI (1) FI111518B (ko)
GR (1) GR3030701T3 (ko)
HU (1) HU219055B (ko)
NO (1) NO316120B1 (ko)
NZ (1) NZ252161A (ko)
PL (1) PL175651B1 (ko)
RU (1) RU2208642C2 (ko)
SG (1) SG50721A1 (ko)
SK (1) SK281086B6 (ko)
WO (1) WO1993024647A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT500650B1 (de) 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
AU2004266216A1 (en) * 2003-08-14 2005-03-03 Ludwig Institute For Cancer Research Anti-Lewis Y anti-idiotypic antibodies and uses thereof
AT504231A1 (de) 2006-10-03 2008-04-15 Hans Dr Loibner Prädiktive parameter
US10150817B2 (en) 2010-09-01 2018-12-11 Biogen Ma Inc. Rapid generation of anti-idiotypic antibodies
RU2735653C2 (ru) * 2016-08-23 2020-11-05 Тран-Сцелл Биологицс Привате Лимитед Платформа с клетками-предшественниками человека для поиска активных веществ лекарственных препаратов

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68926454T2 (de) * 1988-07-06 1997-01-09 Verigen Inc N D Ges Des Staate Gegen hiv 1 gp48 spezifische antikörper
DE4006308A1 (de) * 1990-02-28 1991-08-29 Sandoz Ag Verwendung des monoklonalen antikoerpers br 55.2 gegen kleinzelliges lungenkarzinom
DE4025499A1 (de) * 1990-08-11 1992-02-13 Sandoz Ag Verwendung der antikoerper br55-2, deren derivate, konjugate und fragmente zur bekaempfung von hiv-infektionen
DK0528767T3 (da) * 1991-08-21 2000-04-17 Novartis Ag antistofderivater

Also Published As

Publication number Publication date
NO316120B1 (no) 2003-12-15
RU94046321A (ru) 1997-01-27
CZ286547B6 (cs) 2000-05-17
ES2133395T3 (es) 1999-09-16
DE69324584D1 (de) 1999-05-27
WO1993024647A1 (en) 1993-12-09
SG50721A1 (en) 2000-11-21
FI945485A (fi) 1994-11-22
CA2134751C (en) 2003-12-16
NO944443D0 (no) 1994-11-21
AU4068893A (en) 1993-12-30
JPH11178594A (ja) 1999-07-06
RU2208642C2 (ru) 2003-07-20
NZ252161A (en) 1996-10-28
ATE179214T1 (de) 1999-05-15
JPH07507207A (ja) 1995-08-10
SK281086B6 (sk) 2000-11-07
EP0644947B1 (en) 1999-04-21
CA2134751A1 (en) 1993-12-09
SK139894A3 (en) 1995-07-11
EP0644947A1 (en) 1995-03-29
AU678160B2 (en) 1997-05-22
JP2006143738A (ja) 2006-06-08
NO944443L (no) 1995-01-20
FI111518B (fi) 2003-08-15
DE69324584T2 (de) 1999-09-23
HUT71311A (en) 1995-11-28
DK0644947T3 (da) 1999-11-01
HU219055B (hu) 2001-02-28
GR3030701T3 (en) 1999-11-30
KR100279317B1 (ko) 2001-01-15
PL175651B1 (pl) 1999-01-29
FI945485A0 (fi) 1994-11-22
CZ285194A3 (en) 1995-05-17

Similar Documents

Publication Publication Date Title
NZ568769A (en) Human monoclonal antibodies against CD20
DE69230545D1 (de) Antikörperderivate
NO175944C (no) Monoklonale antistoffer for anvendelse til in vitro påvisning av tumorassosiert mucinantigen, og hybridomcellelinjer som produserer disse
FI840219A0 (fi) Human-humanhybridom foer neoplasmer
NO994983D0 (no) Fremgangsmåte for fremstilling av anti-humane antigenreseptorer, samt anvendelse av disse
ATE171207T1 (de) Monoklonaler antikörper
MX9704898A (es) Anticuerpo anti-idiotipo monoclonal murino 3h1.
OA08485A (fr) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas.
ATE115412T1 (de) Anti-idiotyp-antikörper gegen antimenschliche hochmolekulare, an melanomen assoziierte antigene.
ATE395363T1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen
KR950701685A (ko) 단일클론 항체(monoclonal antibodies)
PT840620E (pt) Antagonistas de il-8 para o tratamento de asma
NO922941D0 (no) Medikamenter og fremgangsmaater for behandling av aids og aids-relatert kompleks ved anvendelse av anti-karbohydrat-antistoffer og karbohydrat-antigener
DE69118702D1 (de) Neue verwendung eines monoklonalen antikörpers
ATE169332T1 (de) Monoklonaler antikörper gegen den extravillösen trophoblast
SE8401946D0 (sv) Antibody to human prostate cancer
ATE343596T1 (de) Humane monoklonale antikörper gegen inselzellantigen ia-2
SE9404491D0 (sv) Process for the production of human monoclonal antibodies
AU6162794A (en) Carcinoma associated antigen (ng1) monoclonal antibodies against ng1, methods of producing these antibodies and use therefor
BG50103A1 (en) Hybridome cell line, secretting monoclonal antibody against antigene determinante noc- 2 of malignant melanom in human
NO874799D0 (no) Fremgangsmaate for fremstilling av monoklonale antistoffer ved dyrking av hybridom-cellelinjen lym-2.
MX9705445A (es) Anticuerpos monoclonales anti-cd6 y su usos.

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20050817

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee